
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. has demonstrated promising advancements in its clinical programs, specifically highlighting WTX-330's favorable safety profile with manageable treatment-emergent adverse events, thus indicating a robust foundation for further clinical studies. The company’s innovative PREDATOR platform, which focuses on conditionally activated molecules, has shown potential in expanding therapeutic applications beyond oncology, as evidenced by the encouraging clinical outcomes of WTX-124 and its superior safety profile compared to traditional IL-2 therapies. Additionally, the ability of these therapies to mitigate systemic toxicity while maintaining enhanced efficacy positions Werewolf Therapeutics favorably in the biopharmaceutical landscape, suggesting significant growth potential as they advance towards clinical expansion.
Bears say
Werewolf Therapeutics Inc has reported a significant increase in net loss, totaling $20.4 million, or $0.46 per share for the fourth quarter of 2024, compared to a loss of $12.0 million for the same period the previous year. The company faces substantial risks related to the clinical and regulatory performance of its lead candidate, WTX-124, which may not achieve acceptable safety, efficacy, or pharmacokinetic properties, potentially impacting its commercialization. Additionally, the current expansion opportunities appear to be undervalued, contributing to an overall negative outlook on the company’s financial prospects.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares